Committee. This meeting is open to the public.

**AGENCY:** Health Care Financing Administration (HCFA), HHS.

The CPAC consists of 15 individuals who are independent actuaries; experts in competitive pricing and the administration of the Federal Employees Health Benefit Program; and representatives of health plans, insurers, employers, unions, and beneficiaries. In accordance with section 4012(a)(5) of the BBA, the CPAC shall terminate on December 31, 2004.

The CPAC held its first meeting on May 7, 1998, and its second meeting on June 24 and 25, 1998. The CPAC members are: James Cubbin, Executive Director, General Motors Health Care Initiative; Robert Berenson, M.D., Director, Center for Health Plans and Providers, HCFA; John Bertko, CEO and Senior Actuary, PM-Squared Inc.; Dave Durenberger, Senior Health Policy Fellow, University of St. Thomas and Founder of Public Policy Partners; Gary Goldstein, M.D., CEO, The Oschner Clinic; Samuel Havens, Healthcare Consultant and Chairman of Health Scope/United; Margaret Jordan, Healthcare Consultant and CEO, The Margaret Jordan Group; Chip Kahn, CEO, The Health Insurance Association of America; Cleve Killingsworth, President, Health Alliance Plan; Nancy Kichak, Director, Office of Actuaries, Office of Personnel Management; Len Nichols, Principal Research Associate, The Urban Institute; Robert Reischauer, President, The Urban Institute; and others.

**DATE:** The meeting is scheduled for September 23, 1998, from 9:00 a.m. until 5:30 p.m. and September 24, 1998, from 9:00 a.m. until 5:30 p.m.

**ADDRESS:** The meeting will be held at the Sheraton Crystal City, 1800 Jefferson Davis Highway, Arlington, Virginia 22202.

**FOR FURTHER INFORMATION CONTACT:** Lu Zawistowich, Sc.D., Executive Director, Competitive Pricing Advisory Committee, Health Care Financing Administration, 7500 Security Boulevard C4–14–17, Baltimore, Maryland 21244–1850, (410) 786–6451.

**SUPPLEMENTARY INFORMATION:** Section 4011 of the Balanced Budget Act of 1997, (BBA) (Public Law 105–33) requires the Secretary of the Department of Health and Human Services (the Secretary) to establish a demonstration project under which payments to Medicare+Choice organizations in designated areas are determined in accordance with a competitive pricing methodology.

**DATES:** The meeting is scheduled for September 23, 1998, from 9:00 a.m. until 5:30 p.m. and September 24, 1998, from 9:00 a.m. until 5:30 p.m.

**ADDRESS:** The meeting will be held at the Sheraton Crystal City, 1800 Jefferson Davis Highway, Arlington, Virginia 22202.

**FOR FURTHER INFORMATION CONTACT:** Lu Zawistowich, Sc.D., Executive Director, Competitive Pricing Advisory Committee, Health Care Financing Administration, 7500 Security Boulevard C4–14–17, Baltimore, Maryland 21244–1850, (410) 786–6451.

**SUPPLEMENTARY INFORMATION:** Section 4011 of the Balanced Budget Act of 1997, (BBA) (Public Law 105–33) requires the Secretary of the Department of Health and Human Services (the Secretary) to establish a demonstration project under which payments to Medicare+Choice organizations in designated areas are determined in accordance with a competitive pricing methodology. Section 4012 of the BBA requires the Secretary to appoint a Competitive Pricing Advisory Committee (the CPAC). The CPAC will meet periodically to make recommendations to the Secretary concerning the designation of areas for inclusion in the project and appropriate research design for implementing the project.

**DATES:** The meeting is scheduled for September 23, 1998, from 9:00 a.m. until 5:30 p.m. and September 24, 1998, from 9:00 a.m. until 5:30 p.m.

**ADDRESS:** The meeting will be held at the Sheraton Crystal City, 1800 Jefferson Davis Highway, Arlington, Virginia 22202.

**FOR FURTHER INFORMATION CONTACT:** Lu Zawistowich, Sc.D., Executive Director, Competitive Pricing Advisory Committee, Health Care Financing Administration, 7500 Security Boulevard C4–14–17, Baltimore, Maryland 21244–1850, (410) 786–6451.

**SUPPLEMENTARY INFORMATION:** Section 4011 of the Balanced Budget Act of 1997, (BBA) (Public Law 105–33) requires the Secretary of the Department of Health and Human Services (the Secretary) to establish a demonstration project under which payments to Medicare+Choice organizations in designated areas are determined in accordance with a competitive pricing methodology. Section 4012 of the BBA requires the Secretary to appoint a Competitive Pricing Advisory Committee (the CPAC). The CPAC will meet periodically to make recommendations to the Secretary concerning the designation of areas for inclusion in the project and appropriate research design for implementing the project.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Health Care Financing Administration**

**[HCFA–1046–N]**

**RIN 0938–AJ14**

**Medicare Program; September 23 and 24, 1998, Meeting of the Competitive Pricing Advisory Committee**

**AGENCY:** Health Care Financing Administration (HCFA), HHS.

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with section 10(a) of the Federal Advisory Committee Act, this notice announces a meeting of the Competitive Pricing Advisory Committee. This meeting is open to the public.

**TABLE 3—ESTIMATING PROSPECTIVE BENEFICIARY EXPENDITURES:**

<table>
<thead>
<tr>
<th>Aged Population</th>
<th>Male 65–69</th>
<th>Female 65+</th>
<th>Male 60–64</th>
<th>Female 60–64</th>
<th>Male 55–59</th>
<th>Female 55–59</th>
<th>Male 45–54</th>
<th>Female 45–54</th>
<th>Male 34–44</th>
<th>Female 34–44</th>
<th>Male 0–34</th>
<th>Female 0–34</th>
<th>Male 95+</th>
<th>Female 95+</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIP–DCG 6</td>
<td>$2792</td>
<td>$5466</td>
<td>$3970</td>
<td>$4768</td>
<td>$3350</td>
<td>$4140</td>
<td>$2654</td>
<td>$3647</td>
<td>$2167</td>
<td>$2763</td>
<td>$1255</td>
<td>$1345</td>
<td>$7189</td>
<td>$5466</td>
</tr>
<tr>
<td>PIP–DCG 7</td>
<td>$3702</td>
<td>$4738</td>
<td>$7209</td>
<td>$3944</td>
<td>$3500</td>
<td>$4040</td>
<td>$2654</td>
<td>$3118</td>
<td>$2188</td>
<td>$2763</td>
<td>$1345</td>
<td>$1345</td>
<td>$6562</td>
<td>$5466</td>
</tr>
<tr>
<td>PIP–DCG 8</td>
<td>$4406</td>
<td>$5829</td>
<td>$9946</td>
<td>$4738</td>
<td>$4800</td>
<td>$5406</td>
<td>$3500</td>
<td>$3944</td>
<td>$2792</td>
<td>$3185</td>
<td>$1400</td>
<td>$1345</td>
<td>$6562</td>
<td>$5466</td>
</tr>
<tr>
<td>PIP–DCG 9</td>
<td>$5829</td>
<td>$9946</td>
<td>$16,346</td>
<td>$7209</td>
<td>$7900</td>
<td>$8900</td>
<td>$4800</td>
<td>$5829</td>
<td>$3944</td>
<td>$4638</td>
<td>$1400</td>
<td>$1345</td>
<td>$6562</td>
<td>$5466</td>
</tr>
<tr>
<td>PIP–DCG 10</td>
<td>$5829</td>
<td>$9946</td>
<td>$16,346</td>
<td>$7209</td>
<td>$7900</td>
<td>$8900</td>
<td>$4800</td>
<td>$5829</td>
<td>$3944</td>
<td>$4638</td>
<td>$1400</td>
<td>$1345</td>
<td>$6562</td>
<td>$5466</td>
</tr>
<tr>
<td>PIP–DCG 11</td>
<td>$7900</td>
<td>$9946</td>
<td>$16,346</td>
<td>$7209</td>
<td>$7900</td>
<td>$8900</td>
<td>$4800</td>
<td>$5829</td>
<td>$3944</td>
<td>$4638</td>
<td>$1400</td>
<td>$1345</td>
<td>$6562</td>
<td>$5466</td>
</tr>
<tr>
<td>PIP–DCG 12</td>
<td>$7900</td>
<td>$9946</td>
<td>$16,346</td>
<td>$7209</td>
<td>$7900</td>
<td>$8900</td>
<td>$4800</td>
<td>$5829</td>
<td>$3944</td>
<td>$4638</td>
<td>$1400</td>
<td>$1345</td>
<td>$6562</td>
<td>$5466</td>
</tr>
<tr>
<td>PIP–DCG 13</td>
<td>$7900</td>
<td>$9946</td>
<td>$16,346</td>
<td>$7209</td>
<td>$7900</td>
<td>$8900</td>
<td>$4800</td>
<td>$5829</td>
<td>$3944</td>
<td>$4638</td>
<td>$1400</td>
<td>$1345</td>
<td>$6562</td>
<td>$5466</td>
</tr>
<tr>
<td>PIP–DCG 14</td>
<td>$7900</td>
<td>$9946</td>
<td>$16,346</td>
<td>$7209</td>
<td>$7900</td>
<td>$8900</td>
<td>$4800</td>
<td>$5829</td>
<td>$3944</td>
<td>$4638</td>
<td>$1400</td>
<td>$1345</td>
<td>$6562</td>
<td>$5466</td>
</tr>
<tr>
<td>PIP–DCG 15</td>
<td>$7900</td>
<td>$9946</td>
<td>$16,346</td>
<td>$7209</td>
<td>$7900</td>
<td>$8900</td>
<td>$4800</td>
<td>$5829</td>
<td>$3944</td>
<td>$4638</td>
<td>$1400</td>
<td>$1345</td>
<td>$6562</td>
<td>$5466</td>
</tr>
</tbody>
</table>

**Previously Disabled Population**

<table>
<thead>
<tr>
<th>Male 65–69</th>
<th>Female 65+</th>
<th>Male 60–64</th>
<th>Female 60–64</th>
<th>Male 55–59</th>
<th>Female 55–59</th>
<th>Male 45–54</th>
<th>Female 45–54</th>
<th>Male 34–44</th>
<th>Female 34–44</th>
<th>Male 0–34</th>
<th>Female 0–34</th>
<th>Male 95+</th>
<th>Female 95+</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIP–DCG 6</td>
<td>$2265</td>
<td>$2265</td>
<td>$2265</td>
<td>$2265</td>
<td>$2265</td>
<td>$2265</td>
<td>$2265</td>
<td>$2265</td>
<td>$2265</td>
<td>$2265</td>
<td>$2265</td>
<td>$2265</td>
<td>$2265</td>
</tr>
</tbody>
</table>
Senior Fellow, The Brookings Institute; John Rother, Director, Legislation and Public Policy, American Association of Retired Persons; Andrew Stern, President, Service Employees International Union, AFL-CIO; and Jay Wolfson, Director, The Florida Information Center, University of South Florida. The Chairperson is James Cubbin and the Co-Chairperson is Robert Berenson, M.D.

The agenda will include observations and points of view on the previous competitive pricing demonstration initiative in Denver from the health plan, provider, employer, beneficiary, and HCFA perspectives. The CPAC will discuss all of the major competitive pricing demonstration design issues and select options that it determines are appropriate for the demonstrations authorized under section 4011 of the BBA.

Individuals or organizations that wish to make 5-minute oral presentations on the agenda issues should contact the Executive Director by 12 noon, September 16, 1998, to be scheduled. The number of oral presentations may be limited by the time available. A written copy of the oral remarks should be submitted to the Executive Director no later than 12 noon, September 18, 1998. Anyone who is not scheduled to speak may submit written comments to the Executive Director by 12 noon, September 18, 1998. The meeting is open to the public, but attendance is limited to the space available.

(Supplementary Information: Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100–71. Subpart C of the Guidelines, “Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies,” sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections. Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards. In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines: ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328–7840 (formerly: Bayshore Clinical Laboratory)


Alliance Laboratory Services, 3200 Burnet Ave. N., Cincinnati, OH 45229, 513–569–2051 (formerly: Jewish Hospital of Cincinnati, Inc.)

American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 20151, 703–802–6900


Associated Regional and University Pathologists, Inc. (ARUP), 500 Chipeta Way, Salt Lake City, UT 84108, 801–583–2787/800–242–2787

Baptist Medical Center—Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501–202–2783 (formerly: Forensic Toxicology Laboratory Baptist Medical Center)

Cedars Medical Center, Department of Pathology, 1400 Northwest 12th Ave., Miami, FL 33136, 305–325–5784


Cox Health Systems, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800–876–3652/417–269–3093 (formerly: Cox Medical Centers)

Dept. of the Navy, Drug Screen Laboratory, Great Lakes, IL, P.O. Box 88–6819, Great Lakes, IL 60088–6819, 847–688–2045/847–688–4171

Diagnostic Services Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, 941–561–8200/800–735–5416

Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31604, 912–244–4468

Drugproof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 800–898–0180/206–386–2672 (formerly: Laboratory of Pathology of Seattle, Inc., Drugproof, Division of Laboratory of Pathology of Seattle, Inc.)

DrugScan, Inc., P.O. Box 2969, 1119 Mears Rd., Warminster, PA 18974, 215–674–9310

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, and Laboratories That Have Withdrewn From the Program

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.